» Articles » PMID: 39538257

Transcriptional Landscape of the Interaction of Human Mesenchymal Stem Cells with Glioblastoma in Bioprinted Co-cultures

Overview
Publisher Biomed Central
Date 2024 Nov 13
PMID 39538257
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The interaction between mesenchymal stem cells (MSC) and Glioblastoma (GBM), although potentially of the highest importance, is ill-understood. This is due, in part, to the lack of relevant experimental models. The similarity between the in vitro situations and the in vivo situation can be improved by 3D co-culture as it reproduces key cell-cell interactions between the tumor microenvironment (TME) and cancer cells.

Methods: MSC Can acquired characteristics of cancer associated fibroblasts (CAF) by being cultured with conditioned medium from GBM cultures and thus are called MSC. We co Cultured MSC with patient derived GBM in a scaffold 3D bioprinted model. We studied the response to current GBM therapy (e.g. Temozolomide + /Radiation) on the co cultures by bulk transcriptomic (RNA Seq) and epigenetic (ATAC Seq) analyses RESULTS: The transcriptomic modifications induced by standard GBM treatment in bioprinted scaffolds of mono- or co-cultures of GBM ± MSC can be analyzed. We found that mitochondrial encoded OXPHOS genes are overexpressed under these conditions and are modified by both co-culture and treatment (chemotherapy ± radiation). We have identified two new markers of MSC/GBM interactions, one epigenetically regulated (i.e. TREM-1) associated with an increased overall survival in GBM patients and another implicated in post-transcriptional regulation (i.e. the long non-coding RNA, miR3681HG), which is associated with a reduced overall survival in GBM patients.

References
1.
Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A . Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-60. DOI: 10.1038/nature05236. View

2.
Bajetto A, Thellung S, Dellacasagrande I, Pagano A, Barbieri F, Florio T . Cross talk between mesenchymal and glioblastoma stem cells: Communication beyond controversies. Stem Cells Transl Med. 2020; 9(11):1310-1330. PMC: 7581451. DOI: 10.1002/sctm.20-0161. View

3.
Jubelin C, Munoz-Garcia J, Griscom L, Cochonneau D, Ollivier E, Heymann M . Three-dimensional in vitro culture models in oncology research. Cell Biosci. 2022; 12(1):155. PMC: 9465969. DOI: 10.1186/s13578-022-00887-3. View

4.
Hattermann K, Fluh C, Engel D, Mehdorn H, Synowitz M, Mentlein R . Stem cell markers in glioma progression and recurrence. Int J Oncol. 2016; 49(5):1899-1910. DOI: 10.3892/ijo.2016.3682. View

5.
Bao S, Wu Q, Li Z, Sathornsumetee S, Wang H, McLendon R . Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res. 2008; 68(15):6043-8. PMC: 2739001. DOI: 10.1158/0008-5472.CAN-08-1079. View